MG ±ö¹û

Developers of innovative drug products dealing with protein formulations, nucleotide-based drugs, peptides, and poorly soluble molecules, face significant challenges in achieving efficient and scalable manufacturing solutions.

Developers of innovative drug products dealing with protein formulations, nucleotide-based drugs, peptides, and poorly soluble molecules, face significant challenges in achieving efficient and scalable manufacturing solutions.

Summary: This article provides an in-depth review of milling equipment, including jet, pin, hammer, conical, and cryogenic mills.

Nasal development is an attractive option but can be difficult, requiring expertise to overcome formulation challenges, and to navigate the complexities of drug/device combination products to optimize drug delivery.

Summary: Originally published in Inhalation magazine, this article discusses how nasal powder formulations represent a significant stride in drug delivery innovation. With drug developers and approvers evolving to address the unique considerations of nasal drug delivery, nasal powders offer a robust and adaptable platform in the pharmaceutical landscape.

Summary: In this article, Dr. Alan Watts, Director of Innovation & Partnerships for Orally Inhaled Products at MG ±ö¹û, and Michael Tauber, Senior Director of Pharmaceutical Development at Acorda Therapeutics discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS can be used to successfully bring new inhaled therapies to market.

Summary: This article discusses how to successfully develop and manufacture spray-dried pulmonary and nasal powders and how a CDMO partner plays an integral role in the successful development and commercialization of inhalation products.

Summary: Download this fact sheet to learn more about our experience and expertise with nitrosamines testing.

In this webinar, experts discuss problems common to the development, testing and manufacturing of intranasal drug products, their potential causes, and possible consequences.

Summary: This article explores the key factors pharmaceutical companies should consider when selecting a CDMO and evaluating its multi-product facility capable of handling HPAPIs to de-risk their programs and bring their products to patients safely.